[Bacteriology of acute exacerbations of chronic obstructive pulmonary disease in Tunisia]. / Bactériologie des exacerbations aiguës des bronchopneumopathies chroniques obstructives en Tunisie.

INTRODUCTION: The role of bacteria, including atypical organisms, in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) has been assessed in various ways in Tunisia. METHODS: This was a descriptive and analytical study of patients with a mean age of 68.3±10.5 years hospitalized for AECOPD. Bacteriological examination included a cytological sputum exam and serology for atypical organisms including Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneumoniae and Legionella pneumophila using standard techniques. RESULTS: Of the 240 patients enrolled, 175 sputum cultures (73%) were considered significant. Twenty-nine cultures were positive (16.5%) and 31 microorganisms were isolated of which the most frequent were P. aeruginosa (25.8%), K. pneumoniae (16.2%), H. influenzae (13%) and S. pneumoniae (9.7%). The prevalence of C. pneumoniae, M. pneumoniae and C. burnetii was 8.4%, 9% and 6.6%, respectively. No L. pneumophila infection was found. The Anthonisen criteria were associated with a positive culture (P=0.04). Almost half (40.9%) of the isolates were resistant to conventional first line antibiotics (43.7% to amoxicillin-clavulanic acid). CONCLUSIONS: Awareness of the low positivity of quantitative sputum bacteriology and the large percentage of resistant strains with a predominance of exclusively multi-resistant Pseudomonas should help in the management of patients with AECOPD.

Prevalence of Chlamydophila pneumoniae and Mycoplasma pneumoniae IgM and IgG antibodies in Tunisian patients presenting with exacerbation of chronic obstructive pulmonary disease.

OBJECTIVE: We aimed to assess the prevalence of Chlamydophila pneumoniae and Mycoplasma pneumoniae acute infections, using serological testing, in patients admitted to the emergency department for acute exacerbations of chronic obstructive pulmonary disease (COPD). METHODS: We performed a prospective observational study of 100 consecutive patients. Serum specimens were collected at day 0 and day 15. C. pneumoniae and M. pneumoniae antibodies (IgM and IgG) were tested by commercial ELISA and immunofluorescence assay, respectively. RESULTS: We did not observe any acute M. pneumoniae infection; however, 11 patients (11%) showed a profile compatible with a recent C. pneumoniae infection (nine patients with specific IgM and two with an IgG antibody rise). Demographic and clinical parameters did not differ between patients with and without biological profile of recent C. pneumoniae infection. CONCLUSION: C. pneumoniae is a pathogen that requires specific antimicrobial treatment. Its detection must always be performed considering its prevalence in patients presenting with acute COPD exacerbations.